Objective: The purpose of this study was to determine if the prevalence of neonatal and maternal infectious morbidity in patients with preterm premature rupture of membranes (PROM) who received ampicillin prophylaxis for presemptive group B streptococcal colonization is increased compared to those who received no prophylaxis. Results: The charts of 206 patients were reviewed; 146 patients received ampicillin for group B streptococcal prophylaxis and 60 patients did not. There was a significantly higher incidence of postpartum endomyometritis among the patients who received ampicillin (62% vs. 22%; P < 0.01).
he goal of the physician managing a patient with preterm premature rupture of the membranes (PROM) is to minimize the risks of both respiratory distress syndrome and maternal and neonatal infection. The etiology of preterm PROM is, however, poorly understood. There is evidence suggesting that an inflammatory process from either a local ascending vaginal or intra-amniotic bacterial infection may weaken the membranes, thus leading to membrane rupture. This has led to numerous trials utilizing antibiotic prophylaxis in patients with preterm PROM. z-6 However, there is no consensus in the literature regarding the choice of antibiotic or the duration of therapy that should be undertaken. Group B streptococcus has been shown to be a risk factor for the development of preterm PROM, neonatal infection, and postpartum febrile morbidity. 1, 7, 8 Numerous studies have shown a reduction in the incidence of early-onset neonatal group B streptococcal disease after maternal antibiotic chemoprophylaxis. 9-1z These studies have led both the American College of Obstetricians and Gynecologists (ACOG) 1" and the American Academy of Pediatrics (AAP) 14 to recommend treatment with either penicillin or ampicillin in patients with unknown status for group B streptococcal colonization who are intrapartum with preterm PROM. Since in most centers the majority of patients would fall into this category, these recommendations would lead to the use of anbibiotics in a large number of patients with preterm PROM. Neither college, however, has defined the duration of therapy in a patient who remains undelivered. The purpose of this study was to determine if the prevalence of neonatal and maternal infectious morbidity in patients with preterm PROM who received ampicillin prophylaxis for presumptive group B streptococcal colonization is increased compared to those who received no prophylaxis. (Table IV) .
SUBJECTS AND METHODS

DISCUSSION
Based on the studies demonstrating that antibiotic prophylaxis reduces the incidence of early neonatal group B streptococcal disease, 9-1e we initiated a policy of routine intrapartum prophylaxis for presumptive group B streptococcal colonization with intravenous ampicillin in all patients with preterm PROM in January 1990. Subsequently, both the ACOG 1 and AAP 14 have passed recommendations endorsing this practice. This policy did not result in a reduction in the incidence of blood cultureproven neonatal sepsis. We found, however, that after the change in policy, postpartum endomyometritis was occurring more often. This resulted in concern that the universal use of ampicillin for group B streptococcal prophylaxis may lead to undesired effects on the maternal and fetal bacterial flora.
Prophylactic antibiotic therapy in patients with preterm PROM has not been shown to reduce the prevalence of blood culture-proven neonatal sep- 
